- Home
- INVA
INVA
Innoviva Inc.
as 07-25-2025 4:00pm EST
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | 1.3B | IPO Year: | 2004 |
| Target Price: | $40.33 | AVG Volume (30 days): | 907.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.67 - $22.00 | Next Earning Date: | 08-04-2025 |
| Revenue: | $369,844,000 | Revenue Growth: | 18.70% |
| Revenue Growth (this year): | 3.75% | Revenue Growth (next year): | 12.62% |
Latest Innoviva Inc. News
INVA Breaking Stock News: Dive into INVA Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Innoviva Says FDA Grants Priority Review to Zoliflodacin NDA for Treating Gonorrhea; Shares Up Pre-Bell
Business Wire
a month ago
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
Argus Research
2 months ago
INVA: Raising target price to $23.00
MT Newswires
2 months ago
Innoviva Says FDA Accepts New Drug Application for Zoliflodacin
Business Wire
2 months ago
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
Business Wire
2 months ago
Innoviva to Participate in Upcoming Investor Conferences
Argus Research
2 months ago
INVA: Raising target price to $20.00
Business Wire
2 months ago
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
Compare INVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INVA Innoviva Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.